Cargando…

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer

Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly paclitaxel wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghebeh, Hazem, Al-Sayed, Adher, Eiada, Riham, Cabangon, Leilani, Ajarim, Dahish, Suleman, Kausar, Tulbah, Asma, Al-Tweigeri, Taher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476586/ https://www.ncbi.nlm.nih.gov/pubmed/34580336 http://dx.doi.org/10.1038/s41598-021-98113-6

Ejemplares similares

Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination
por: Al Sayed, Adher D., et al.
Publicado: (2019)

Fascin Is a Key Regulator of Breast Cancer Invasion That Acts via the Modification of Metastasis-Associated Molecules
por: Al-Alwan, Monther, et al.
Publicado: (2011)

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population
por: Osmani, Asif Husain, et al.
Publicado: (2021)

Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
por: Al-Tweigeri, Taher, et al.
Publicado: (2021)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

Association Between Obesity and Clinicopathological Profile of Patients with Newly Diagnosed Non-Metastatic Breast Cancer in Saudi Arabia
por: Alshamsan, Bader, et al.
Publicado: (2022)

Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience
por: Elkum, Naser, et al.
Publicado: (2007)

FOXP3(+ )T(regs )and B7-H1(+)/PD-1(+ )T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
por: Ghebeh, Hazem, et al.
Publicado: (2008)

Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis
por: Qattan, Amal, et al.
Publicado: (2021)

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
por: Alsuliman, Abdullah, et al.
Publicado: (2015)

β1 Integrin is essential for fascin‐mediated breast cancer stem cell function and disease progression
por: Barnawi, Rayanah, et al.
Publicado: (2019)

High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer
por: Siraj, Abdul K, et al.
Publicado: (2021)

Obesity is a significant risk factor for breast cancer in Arab women
por: Elkum, Naser, et al.
Publicado: (2014)

Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues
por: Ghebeh, Hazem, et al.
Publicado: (2021)

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway
por: Ghebeh, H, et al.
Publicado: (2014)

Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer
por: Qattan, Amal, et al.
Publicado: (2022)

PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2021)

Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women
por: Colak, Dilek, et al.
Publicado: (2013)

Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
por: Ghebeh, Hazem, et al.
Publicado: (2010)

Behavior and Outcomes of Pregnancy Associated Breast Cancer
por: Suleman, Kausar, et al.
Publicado: (2019)

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
por: Ghebeh, Hazem, et al.
Publicado: (2015)

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment
por: Siraj, Abdul Khalid, et al.
Publicado: (2018)

Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis
por: Bu, Rong, et al.
Publicado: (2016)

High DNMT1 Expression in Stromal Fibroblasts Promotes Angiogenesis and Unfavorable Outcome in Locally Advanced Breast Cancer Patients
por: Al-Kharashi, Layla A., et al.
Publicado: (2022)

ALK alteration is a frequent event in aggressive breast cancers
por: Siraj, Abdul K., et al.
Publicado: (2015)

FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer
por: Siraj, Abdul Khalid, et al.
Publicado: (2018)

Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
por: Siraj, Abdul Khalid, et al.
Publicado: (2021)

Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients
por: Al-Ansari, Mysoon M., et al.
Publicado: (2020)

Profiling of normal and malignant breast tissue show CD44(high)/CD24(low) phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers
por: Ghebeh, Hazem, et al.
Publicado: (2013)

Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients
por: Ezzat, A A, et al.
Publicado: (2004)

The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females
por: Al-Moghrabi, Nisreen, et al.
Publicado: (2014)

High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients
por: Al-Tweigeri, Taher, et al.
Publicado: (2022)

PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients
por: Siraj, Abdul K., et al.
Publicado: (2023)

Successful outcome of Langerhans cell histiocytosis complicated by therapy-related myelodysplasia and acute myeloid leukemia: a case report
por: Al-Anazi, Khalid A, et al.
Publicado: (2008)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
por: Nishino, Kazumi, et al.
Publicado: (2020)

PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis
por: Mansour, Fatmah A., et al.
Publicado: (2020)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_320vueollg045te8me85u1e3al